Future investigations are warranted to precisely define whether the documentation of NPM1 gene mutation per se may become sufficient, in the appropriate clinical setting, to classify MNs as NPM1-mutated AML, independently of the blast cell count [5,69]. This evidence concerns the gene NPM1 and acute myeloid leukemia.